# Pitney Bowes Inc: financial statements, quarterly

PBI · NYSE · CIK 78814 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pbi.md) · [Financials](/companies/pbi/financials.md) · [Filings](/companies/pbi/filings.md) · [Insiders](/companies/pbi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pbi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [526](/filings/0000078814-25-000015.md) | [521](/filings/0001628280-25-023713.md) | [490](/filings/0001628280-25-036856.md) | [499](/filings/0001628280-25-047360.md) | [516](/filings/0000078814-25-000015.md) | [493](/filings/0001628280-26-031003.md) | [462](/filings/0001628280-26-050908.md) | [460](/filings/0001628280-26-068089.md) | [478 d](/filings/0001628280-26-009921.md) | [477](/filings/0001628280-26-031003.md) | [451](/filings/0001628280-26-050908.md) | [456](/filings/0001628280-26-068089.md) |
| Cost of revenue | $m | [259](/filings/0000078814-25-000015.md) | [249](/filings/0000078814-25-000015.md) | [239](/filings/0000078814-25-000015.md) | [238](/filings/0000078814-25-000015.md) | [239](/filings/0000078814-25-000015.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [8.1 d](/filings/0001628280-26-009921.md) | [7.6](/filings/0001628280-25-023713.md) | [7.3](/filings/0001628280-25-036856.md) | [7.6](/filings/0001628280-25-047360.md) | [9.5 d](/filings/0001628280-26-009921.md) | [4.8](/filings/0001628280-26-031003.md) | [3.6](/filings/0001628280-26-050908.md) | [3.4](/filings/0001628280-26-068089.md) | [3.5 d](/filings/0001628280-26-009921.md) | [3.8](/filings/0001628280-26-031003.md) | [3.4](/filings/0001628280-26-050908.md) | [3.4](/filings/0001628280-26-068089.md) |
| Selling, general and administrative | $m | [198 d](/filings/0001628280-26-009921.md) | [187](/filings/0001628280-25-023713.md) | [193](/filings/0001628280-25-036856.md) | [190](/filings/0001628280-25-047360.md) | [148 d](/filings/0001628280-26-009921.md) | [166](/filings/0001628280-26-031003.md) | [171](/filings/0001628280-26-050908.md) | [144](/filings/0001628280-26-068089.md) | [141 d](/filings/0001628280-26-009921.md) | [133](/filings/0001628280-26-031003.md) | [129](/filings/0001628280-26-050908.md) | [139](/filings/0001628280-26-068089.md) |
| Interest expense | $m | [28.4 d](/filings/0000078814-24-000004.md) | [27.8](/filings/0000078814-24-000026.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(1.0)](/filings/0000078814-25-000015.md) | [15.5](/filings/0001628280-25-023713.md) | [2.3](/filings/0001628280-25-036856.md) | [(166)](/filings/0001628280-25-047360.md) | [(6.1)](/filings/0000078814-25-000015.md) | [11.3](/filings/0001628280-26-031003.md) | [9.3](/filings/0001628280-26-050908.md) | [16.2](/filings/0001628280-26-068089.md) | [11.0 d](/filings/0001628280-26-009921.md) | [22.3](/filings/0001628280-26-031003.md) | [15.6](/filings/0001628280-26-050908.md) | [17.4](/filings/0001628280-26-068089.md) |
| Net income | $m | [(224)](/filings/0000078814-25-000015.md) | [(2.9)](/filings/0001628280-25-023713.md) | [(24.9)](/filings/0001628280-25-036856.md) | [(138)](/filings/0001628280-25-047360.md) | [(37.4)](/filings/0000078814-25-000015.md) | [35.4](/filings/0001628280-26-031003.md) | [30.0](/filings/0001628280-26-050908.md) | [52.0](/filings/0001628280-26-068089.md) | [27.3 d](/filings/0001628280-26-009921.md) | [58.1](/filings/0001628280-26-031003.md) | [49.9](/filings/0001628280-26-050908.md) | [52.7](/filings/0001628280-26-068089.md) |
| Diluted EPS | $ per share | [(1.27)](/filings/0000078814-25-000015.md) | [(0.02)](/filings/0001628280-25-023713.md) | [(0.14)](/filings/0001628280-25-036856.md) | [(0.75)](/filings/0001628280-25-047360.md) | [(0.21)](/filings/0000078814-25-000015.md) | [0.19](/filings/0001628280-26-031003.md) | [0.17](/filings/0001628280-26-050908.md) | [0.30](/filings/0001628280-26-068089.md) | not reported | [0.39](/filings/0001628280-26-031003.md) | [0.36](/filings/0001628280-26-050908.md) | [0.37](/filings/0001628280-26-068089.md) |
| Basic EPS | $ per share | [(1.27)](/filings/0000078814-25-000015.md) | [(0.02)](/filings/0001628280-25-023713.md) | [(0.14)](/filings/0001628280-25-036856.md) | [(0.77)](/filings/0001628280-25-047360.md) | [(0.21)](/filings/0000078814-25-000015.md) | [0.19](/filings/0001628280-26-031003.md) | [0.17](/filings/0001628280-26-050908.md) | [0.31](/filings/0001628280-26-068089.md) | not reported | [0.40](/filings/0001628280-26-031003.md) | [0.37](/filings/0001628280-26-050908.md) | [0.39](/filings/0001628280-26-068089.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [600](/filings/0001628280-26-009921.md) | [516](/filings/0000078814-24-000026.md) | [590](/filings/0000078814-24-000051.md) | [562](/filings/0000078814-24-000067.md) | [470](/filings/0001628280-26-009921.md) | [324](/filings/0001628280-25-023713.md) | [285](/filings/0001628280-25-036856.md) | [321](/filings/0001628280-25-047360.md) | [285](/filings/0001628280-26-068089.md) | [303](/filings/0001628280-26-031003.md) | [267](/filings/0001628280-26-050908.md) | [269](/filings/0001628280-26-068089.md) |
| Current assets | $m | [2,058](/filings/0000078814-25-000015.md) | [1,582](/filings/0000078814-24-000026.md) | [1,606](/filings/0000078814-24-000051.md) | [1,486](/filings/0000078814-24-000067.md) | [1,318](/filings/0001628280-26-009921.md) | [1,185](/filings/0001628280-25-023713.md) | [1,126](/filings/0001628280-25-036856.md) | [1,150](/filings/0001628280-25-047360.md) | [1,100](/filings/0001628280-26-068089.md) | [1,129](/filings/0001628280-26-031003.md) | [1,040](/filings/0001628280-26-050908.md) | [1,045](/filings/0001628280-26-068089.md) |
| Total assets | $m | [4,272](/filings/0001628280-26-009921.md) | [4,103](/filings/0000078814-24-000026.md) | [4,078](/filings/0000078814-24-000051.md) | [3,648](/filings/0000078814-24-000067.md) | [3,398](/filings/0001628280-26-009921.md) | [3,270](/filings/0001628280-25-023713.md) | [3,239](/filings/0001628280-25-036856.md) | [3,255](/filings/0001628280-25-047360.md) | [3,169](/filings/0001628280-26-068089.md) | [3,147](/filings/0001628280-26-031003.md) | [3,020](/filings/0001628280-26-050908.md) | [2,992](/filings/0001628280-26-068089.md) |
| Current liabilities | $m | [1,898](/filings/0000078814-25-000015.md) | [1,625](/filings/0000078814-24-000026.md) | [1,678](/filings/0000078814-24-000051.md) | [1,685](/filings/0000078814-24-000067.md) | [1,673](/filings/0001628280-26-009921.md) | [1,489](/filings/0001628280-25-023713.md) | [1,489](/filings/0001628280-25-036856.md) | [1,422](/filings/0001628280-25-047360.md) | [1,548](/filings/0001628280-26-068089.md) | [1,818](/filings/0001628280-26-031003.md) | [1,418](/filings/0001628280-26-050908.md) | [1,497](/filings/0001628280-26-068089.md) |
| Total liabilities | $m | [4,641](/filings/0000078814-25-000015.md) | [4,495](/filings/0000078814-24-000026.md) | [4,506](/filings/0000078814-24-000051.md) | [4,167](/filings/0000078814-24-000067.md) | [3,976](/filings/0001628280-26-009921.md) | [3,806](/filings/0001628280-25-023713.md) | [3,776](/filings/0001628280-25-036856.md) | [3,917](/filings/0001628280-25-047360.md) | [3,971](/filings/0001628280-26-068089.md) | [4,041](/filings/0001628280-26-031003.md) | [3,883](/filings/0001628280-26-050908.md) | [3,829](/filings/0001628280-26-068089.md) |
| Long-term debt | $m | [2,087](/filings/0000078814-25-000015.md) | [2,076](/filings/0000078814-24-000026.md) | [2,065](/filings/0000078814-24-000051.md) | [2,052](/filings/0000078814-24-000067.md) | [1,866](/filings/0001628280-26-009921.md) | [1,899](/filings/0001628280-25-023713.md) | [1,882](/filings/0001628280-25-036856.md) | [2,088](/filings/0001628280-25-047360.md) | [1,976](/filings/0001628280-26-068089.md) | [1,774](/filings/0001628280-26-031003.md) | [2,011](/filings/0001628280-26-050908.md) | [1,863](/filings/0001628280-26-068089.md) |
| Current portion of debt | $m | [58.9](/filings/0000078814-25-000015.md) | [58.1](/filings/0000078814-24-000026.md) | [57.3](/filings/0000078814-24-000051.md) | [56.5](/filings/0000078814-24-000067.md) | [53.3](/filings/0001628280-26-009921.md) | [14.2](/filings/0001628280-25-023713.md) | [15.2](/filings/0001628280-25-036856.md) | [16.2](/filings/0001628280-25-047360.md) | [17.2](/filings/0001628280-26-068089.md) | [364](/filings/0001628280-26-031003.md) | [23.1](/filings/0001628280-26-050908.md) | [24.7](/filings/0001628280-26-068089.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(369)](/filings/0001628280-26-009921.md) | [(392)](/filings/0001628280-25-036856.md) | [(428)](/filings/0001628280-25-047360.md) | [(519)](/filings/0001628280-25-047360.md) | [(578)](/filings/0001628280-26-068089.md) | [(536)](/filings/0001628280-26-050908.md) | [(537)](/filings/0001628280-26-068089.md) | [(662)](/filings/0001628280-26-068089.md) | [(802)](/filings/0001628280-26-068089.md) | [(894)](/filings/0001628280-26-050908.md) | [(863)](/filings/0001628280-26-068089.md) | [(837)](/filings/0001628280-26-068089.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [94.0 d](/filings/0001628280-26-009921.md) | [(12.6)](/filings/0001628280-25-023713.md) | [92.6 d](/filings/0001628280-25-036856.md) | [14.7 d](/filings/0001628280-25-047360.md) | [134 d](/filings/0001628280-26-009921.md) | [(16.7)](/filings/0001628280-26-031003.md) | [111 d](/filings/0001628280-26-050908.md) | [66.8 d](/filings/0001628280-26-068089.md) | [222 d](/filings/0001628280-26-009921.md) | [44.2](/filings/0001628280-26-031003.md) | [153 d](/filings/0001628280-26-050908.md) | [151 d](/filings/0001628280-26-068089.md) |
| Capital expenditure | $m | [27.9 d](/filings/0001628280-26-009921.md) | [14.3](/filings/0001628280-25-023713.md) | [16.5 d](/filings/0001628280-25-036856.md) | [19.4 d](/filings/0001628280-25-047360.md) | [22.2 d](/filings/0001628280-26-009921.md) | [16.9](/filings/0001628280-26-031003.md) | [13.3 d](/filings/0001628280-26-050908.md) | [15.8 d](/filings/0001628280-26-068089.md) | [20.3 d](/filings/0001628280-26-009921.md) | [15.8](/filings/0001628280-26-031003.md) | [18.5 d](/filings/0001628280-26-050908.md) | [10.7 d](/filings/0001628280-26-068089.md) |
| Dividends paid | $m | [8.9 d](/filings/0001628280-26-009921.md) | [8.8](/filings/0001628280-25-023713.md) | [9.0 d](/filings/0001628280-25-036856.md) | [9.1 d](/filings/0001628280-25-047360.md) | [9.1 d](/filings/0001628280-26-009921.md) | [11.0](/filings/0001628280-26-031003.md) | [12.6 d](/filings/0001628280-26-050908.md) | [13.3 d](/filings/0001628280-26-068089.md) | [14.2 d](/filings/0001628280-26-009921.md) | [13.3](/filings/0001628280-26-031003.md) | [13.6 d](/filings/0001628280-26-050908.md) | [13.7 d](/filings/0001628280-26-068089.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [175](/filings/0000078814-24-000026.md) | [176](/filings/0000078814-23-000026.md) | [180](/filings/0000078814-24-000067.md) | [181](/filings/0001628280-25-023713.md) | [179](/filings/0001628280-25-036856.md) | [184](/filings/0001628280-25-047360.md) | [185](/filings/0001628280-26-031003.md) | [181](/filings/0001628280-26-050908.md) | [170](/filings/0001628280-26-068089.md) | [148](/filings/0001628280-26-031003.md) | [139](/filings/0001628280-26-050908.md) | [141](/filings/0001628280-26-068089.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 135,554,541 at 2026-10-20, from the cover of the [10-Q filed 2026-10-29](/filings/0001628280-26-068089.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 14:06 ET. No prices; not investment advice.